Biotech Decliners: Ocera Therapeutics Inc (NASDAQ:OCRX), Marina Biotech, Inc. (OTCMKTS:MRNA), CorMedix Inc. (NYSEMKT:CRMD), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Ocera Therapeutics Inc (NASDAQ:OCRX) is a company with one main value driver, OCR002. Financially, the company is now sitting on $47.2 M and will be spending $30M in the 2014 financial year. It has about one year in cash. Last year, it spent $3.5M in R&D and these costs are set to increase as it ramps up the Phase 2 trials for OCR002. Ocera Therapeutics … Continue reading Biotech Decliners: Ocera Therapeutics Inc (NASDAQ:OCRX), Marina Biotech, Inc. (OTCMKTS:MRNA), CorMedix Inc. (NYSEMKT:CRMD), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

John Meady04/0104/01

Bearish Stocks: MannKind Corporation (NASDAQ:MNKD), Prana Biotechnology Limited (NASDAQ:PRAN), Oi SA (ADR) (NYSE:OIBR), Idera Pharmaceuticals (NASDAQ:IDRA)

Shares of MannKind Corp. (NASDAQ:MNKD) fall as much as 27.105% prior to Tuesday’s Endocrinologic and Metabolic Drugs Advisory Committee Meeting. MannKind Corporation (NASDAQ:MNKD) stock performance was -16.77% in last session and finished the day at $4.02. Traded volume was 30,207,668 million shares in the last session and the average volume of the stock remained 7.92 million shares. The beta of the stock remained 1.47. MannKind … Continue reading Bearish Stocks: MannKind Corporation (NASDAQ:MNKD), Prana Biotechnology Limited (NASDAQ:PRAN), Oi SA (ADR) (NYSE:OIBR), Idera Pharmaceuticals (NASDAQ:IDRA)

Colin Pettis04/0104/01

Bullish Stocks at NASDAQ: InterCloud Systems (NASDAQ:ICLD), Idera Pharmaceuticals (NASDAQ:IDRA), Parametric Sound (NASDAQ:PAMT), VisionChina Media (NASDAQ:VISN)

Glancy Binkow & Goldberg LLP, representing investors of InterCloud Systems, Inc. (NASDAQ:ICLD), has filed a class action lawsuit in the United States District Court for the District of New Jersey on behalf of a class comprising all purchasers of InterCloud securities between November 5, 2013 and March 17, 2014, inclusive (the “Class Period”). InterCloud Systems Inc. (NASDAQ:ICLD) stock performance was 22.58% in last session and … Continue reading Bullish Stocks at NASDAQ: InterCloud Systems (NASDAQ:ICLD), Idera Pharmaceuticals (NASDAQ:IDRA), Parametric Sound (NASDAQ:PAMT), VisionChina Media (NASDAQ:VISN)

Jayne Crisman03/3103/31

FB Nasdaq FB Facebook

Biotech Bullish Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Idera Pharmaceuticals (NASDAQ:IDRA), CytRx Corporation (NASDAQ:CYTR), Corcept Therapeutics Incorporated (NASDAQ:CORT)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is 6.6% higher, as traders digest rumors that Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was willing to pay over $20 per share to buy the firm. Digging deeper, speculators are expecting ARIA to remain south of $9 in the short term, buying to open the April 9 and May 9 puts. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was 5.00% in last session and … Continue reading Biotech Bullish Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Idera Pharmaceuticals (NASDAQ:IDRA), CytRx Corporation (NASDAQ:CYTR), Corcept Therapeutics Incorporated (NASDAQ:CORT)

Jason Knox03/3103/31

Biotech Gainers: Geron Corporation (NASDAQ:GERN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Opexa Therapeutics Inc. (NASDAQ:OPXA)

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Geron Corporation (NASDAQ:GERN) securities during the period between June 16, 2013 and March 11, 2014, inclusive (the “Class Period”). Geron Corporation (NASDAQ:GERN) stock performance was 39.33% in last session and finished the day at … Continue reading Biotech Gainers: Geron Corporation (NASDAQ:GERN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Opexa Therapeutics Inc. (NASDAQ:OPXA)

John Bellich03/1903/19

Biotech Gainers: Neuralstem (NYSEMKT:CUR), OXiGENE Inc (NASDAQ:OXGN), Idera Pharmaceuticals (NASDAQ:IDRA), Five Prime Therapeutics (NASDAQ:FPRX)

Shares of Neuralstem (NYSEMKT:CUR) , a clinical-stage biopharmaceutical company focused on treating central nervous system disorders through neural stem-cell therapies, advanced as much as 13% after reporting final phase 1 results utilizing NSI-566 in treating amyotrophic lateral sclerosis. Neuralstem, Inc. (NYSEMKT:CUR) stock performance was 12.05% in last session and finished the day at $4.37. Traded volume was 4,029,043 million shares in the last session and … Continue reading Biotech Gainers: Neuralstem (NYSEMKT:CUR), OXiGENE Inc (NASDAQ:OXGN), Idera Pharmaceuticals (NASDAQ:IDRA), Five Prime Therapeutics (NASDAQ:FPRX)

Mark Doerr03/1803/18